Lonely / Shutterstock.com
The Pharmaq v Intervet SPC decision leaves open the question of just how similar to the authorised active ingredient an infringing generic product needs to be. Sam Bailey of Mewburn Ellis reports.
Supplementary protection certificates (SPCs) offer valuable extensions to the protection offered by the patent system for new pharmaceuticals and plant protection products in Europe. They have the potential to provide up to five years of additional protection for the product on the expiry of the basic patent to compensate the innovator for the delay in commercial exploitation due to extended authorisation procedures required to bring these products to market.
When the SPC regulation came into force in 1993, a large portion of new pharmaceutical products were small molecule therapeutics with easily defined chemical structures. However, recent trends towards more complex therapeutic products including antibodies, vaccines, combination therapies, and biologics in general are presenting severe tests to both the wording of the SPC regulation and the legal reasoning of the national and European courts.
A case from the Oslo District Court, Pharmaq v Intervet International (August 2015), has attracted interest in the SPC field not least due to the unusual reference to the European Free Trade Association (EFTA) Court for clarification on interpretation of SPC law, but also due to the broad interpretation of the scope of SPCs for vaccines to encompass the exact product and also therapeutic equivalents. While this decision is clearly in favour of the holders of SPCs for therapeutic biologics, it also presents significant uncertainties about the exact scope of protection of an SPC which will certainly occupy the appeals court in this case and seems likely to arise again in EU court proceedings in the future.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
SPCs, Sam Bailey, Mewburn Ellis, EFTA, EU, SAV-1, CJEU, patent, Arne Forsgren v Österreichisches Patentamt,